TMEM106A and hepatocellular carcinoma: TMEM106A is markedly downregulated (often via promoter methylation). Highly metastatic HCC cells exhibit lower TMEM106A levels, and these low levels predict poor postoperative survival. Re‐expression inhibits migration, invasion, and lung metastases, functioning as an anti‐metastatic suppressor.